INKT Overview

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Wall Street analysts forecast INKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INKT is35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mink Therapeutics Inc revenue for the last quarter amounts to -2.88M USD, increased 13.78

Mink Therapeutics Inc. EPS for the last quarter amounts to USD, decreased

Mink Therapeutics Inc (INKT) has 15 emplpoyees as of May 31 2026.

Today INKT has the market capitalization of 60.78M USD.